BlueCrest Capital Management’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

BlueCrest Capital Management’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-200,000	Closed	-$2M	–	514
2021 Q2	$2M	Hold	200,000	–	–	0.04%	321
2021 Q1	$2.01M	Buy	+200,000	New	+$2M	0.03%	472

Other funds holding EBACU

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $871M AUM 8.61% 1-Year Est. Return

BlueCrest Capital Management's EBACU Position: Q3 2021 in Review

BlueCrest Capital Management sold out of European Biotech Acquisition Corp. Units (EBACU) in Q3 2021, closing a stake of 200,000 shares — an estimated $2M sold.

BlueCrest Capital Management first reported a position in EBACU in Q1 2021 and held it in 2 quarters. The position peaked at $2.01M in Q1 2021. 30 funds tracked by Wall St. Rank hold EBACU as of Q3 2021.

BlueCrest Capital Management reported no remaining European Biotech Acquisition Corp. Units position as of Q3 2021 after selling out during the quarter.
BlueCrest Capital Management sold 200,000 European Biotech Acquisition Corp. Units shares in Q3 2021, an estimated $2M.
BlueCrest Capital Management first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 2 quarters.
BlueCrest Capital Management's European Biotech Acquisition Corp. Units position peaked at $2.01M in Q1 2021.
30 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q3 2021.

Based on BlueCrest Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.